Skip to content

Discontinued — last reported Q3 '20

Deferred Revenue at other companies

Ardelyx logo
ArdelyxARDX
$3.25M-70.2%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$48K-96.3%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$69.2M-14.7%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$6.28M-23.2%
TG Therapeutics logo
TG TherapeuticsTGTX
$6.86M+4.0%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$2M-52.9%

Other financials

Income statement

See full
Revenue$106.5M+159%
Operating income$72.6M+349%
Net income$40.8M+209%
EPS (diluted)$0.24+204%

Balance sheet

See full
Cash & equivalents$220.5M+103%
Total debt$212.4M+1,323%
Total equity-$217.1M+35.0%
Total assets$434.6M+32.8%

Cash flow

See full
Operating cash flow$5.1M-74.3%
CapEx-
Free cash flow$74.6M+390%

Valuation

See full
Market cap$632.12M+457%
Enterprise value$624M+3,024%
P/E6.2×
P/S1.8×+1.4×

Profitability

See full
Gross margin99.2%
Operating margin55.4%+38.7pp
Net margin28.3%+22.3pp
FCF margin24.7%-11.1pp

Returns & leverage

See full
Return on equity29.7%-138pp
Debt / equity-0.5×
Current ratio1.4×-1.9×

Where this comes from

Reported directly by Ironwood Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The official record: Ironwood Pharmaceuticals’s 10-Q, filed November 5, 2020, on SEC EDGAR. View the filing →

Questions, answered.

What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.